Related Experiment Video
Updated: May 23, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms
Viktor Hamrefors1, Marketa Sjögren, Peter Almgren
1Department of Clinical Sciences, Lund University, Malmö, Norway. Viktor.Hamrefors@med.lu.se
Journal of Hypertension
|April 25, 2012
Summary
Most blood pressure-associated single-nucleotide polymorphisms (SNPs) do not impact blood pressure reduction from common antihypertensive medications. Two SNPs showed nominal associations, but require further testing for clinical relevance in polygenic essential hypertension.
Area of Science:
- Pharmacogenomics
- Cardiovascular Genetics
- Internal Medicine
Background:
- Single-nucleotide polymorphisms (SNPs) associated with blood pressure (BP) are increasingly identified.
- Understanding their role in antihypertensive treatment response is crucial for personalized medicine.
Purpose of the Study:
- To investigate whether eight common BP-associated SNPs influence BP reduction with specific antihypertensive agents.
- To explore potential pharmacogenetic interactions in hypertensive patients.
Main Methods:
- A cohort of 3863 Swedish hypertensive patients was analyzed.
- The number of unfavorable alleles for eight SNPs was correlated with BP reduction after 6 months of monotherapy with beta-blockers, thiazide diuretics, or diltiazem.
Main Results:
- Six SNPs showed no significant pharmacogenetic interactions.
- PLCD3-rs12946454 and CYP17A1-rs11191548 exhibited nominal associations with treatment response, but these were attenuated after adjusting for multiple testing.
- Associations varied depending on the specific drug class (diltiazem, beta-blockers, or diuretics).
Conclusions:
- Major pharmacogenetic interactions between these eight SNPs and the studied antihypertensive drugs are unlikely.
- Further research is needed to validate the nominal findings for rs12946454 and rs11191548 and assess their clinical utility in treating polygenic essential hypertension.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...